Filing Flows › Health Care › Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics (KPTI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Karyopharm Therapeutics (KPTI) Q2 2026 earnings results →
Q2 2026 Revenue down 12% year over year to $33.4M · 200¢ of every $1 of revenue lost · operating margin -67.4%
Karyopharm Therapeutics made $33.4M in Q2 2026 (-12% Y/Y): Product $30.8M, License and Other $2.7M. Operating margin -67.4%, net loss $67.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $33.4M in Q2 2026, down 12% year over year and down 5% from the previous quarter. Product was the largest line at 92% of revenue. License and Other lost $5.6M year over year (down 68%), 124% of the total change.
Operating costs exceeded revenue by $22.5M, an operating margin of -67.4%. Total costs fell 10% while revenue fell 12%. The quarter ended with a net loss of $67.0M, wider than the previous quarter's $22.4M loss. Net interest and other expense of $44.5M was the main reason.
Operating cash flow was −$24.9M. Non-cash charges added back $1.9M of share-based compensation. Working capital and other items added $40.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $33.4M | -12% | -67.4% | −$67.0M | −$24.9M |
| Q1 2026 | 10-Q | May 14, 2026 | $35.1M | +17% | -76.3% | −$22.4M | −$22.7M |
| Q4 2025 | 10-K | Feb 13, 2026 | $34.1M | +12% | -52.4% | −$102M | −$11.8M |
| Q3 2025 | 10-Q | Nov 3, 2025 | $44.0M | +14% | -34.6% | −$33.1M | −$5.9M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $37.9M | -11% | -64.3% | −$37.3M | −$18.7M |
| Q1 2025 | 10-Q | May 12, 2025 | $30.0M | -9% | -110.8% | −$23.5M | −$39.0M |
| Q4 2024 | 10-K | Feb 19, 2025 | $30.5M | -10% | -102.4% | −$30.8M | −$25.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor.
In its own words, from its 8-K, filed Aug 13, 2026.
Karyopharm Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -12% against the peers' median +7%. Operating margin: -67.4% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Q2 2026 | $33.4M | -12% | -67.4% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Karyopharm Therapeutics 10-Q on SEC EDGAR · CIK 1503802 · Pharmaceutical Preparations
13F: who owns KPTI and who is buying
More on KPTI
- How Karyopharm Therapeutics makes money: revenue by segment
- Karyopharm Therapeutics next earnings date and what analysts expect
- Karyopharm Therapeutics stock forecast, price target and fair value
- Who owns Karyopharm Therapeutics stock: holders, funds and Congress trades
- Karyopharm Therapeutics recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results
Compare KPTI with
- Karyopharm Therapeutics vs Actinium Pharmaceuticals (KPTI vs ATNM)
- Karyopharm Therapeutics vs Bicycle Therapeutics (KPTI vs BCYC)
- Karyopharm Therapeutics vs Gyre Therapeutics (KPTI vs GYRE)
- Karyopharm Therapeutics vs Macrogenics (KPTI vs MGNX)
- Karyopharm Therapeutics vs Elite Pharmaceuticals (KPTI vs ELTP)